Beyond Infection: The Realities of Primary Immunodeficiency. A CE Supplement
Jointly provided by Educational Review Systems and Ig National Society, Inc.
This activity is supported by independent educational grants from Pfizer, Inc. and Takeda.
Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.
Educational Objectives
Upon completion of this activity, participants should be able to:
Lesson 1: Secondary Immune Deficiences from Biological Agents
- Review the nomenclature for monoclonal antibodies
- Explain the mechanisms for prolonged hypogammaglobulinemia with Rituximab
- Review the immune and infectious consequences of some of the most frequently used biologics on the immune system
- Review the adverse effects of immune check point inhibitors
Lesson 2: Autoinflammatory Disorders
- Define autoinflammatory disorders
- Discuss the role of phenotyping and family history in the diagnosis of autoinflammatory disease
- Describe the basis of inflammasome-mediated inflammation
- Describe the role of cytokine-targeting biologics as therapy for these disorders
Lesson 3: Immune Dysregulation – A New Facet of Primary Immunodeficiency Disease (PIDD)
- Discuss non-infectious presentations and manifestations of primary immunodeficiency
- Formulate a differential diagnosis for children with suspected immunodeficiency
- Identify new rare defects of the immune system that cause immunodeficiency
Lesson 4: Pulmonary complications of primary immunodeficiency
- Explain key aspects of the pathogenesis and clinical presentation of pulmonary disease in primary immunodeficiency
- Summarize our understanding of asthma and chronic obstructive pulmonary disease in primary immunodeficiency
- Recognize the physiology, clinical presentation, and therapeutic approach to bronchiectasis in primary immunodeficiency
- Identify distinct forms of interstitial lung disease occurring in primary immunodeficiency
Lesson 5: The Complex PI Patient: The Tangled Web of Immunodeficiency and Its Complications
- Learn the range of disorders of host defense.
- Understand the non-infectious co-morbidities associated with PI.
- Discern pediatric and adult PI patient differences pertaining to treatment and clinical outcomes.
- Learn the complexity of PI patients’ comorbidities and risk factors.
Faculty and Planner Disclosure of Financial Relationships
Educational Review Systems requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Educational Review Systems policy. Educational Review Systems is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Faculty
Mark Ballow, MD
Conflicts of Interest
No relevant financial relationships
Faculty
Lori Broderick, MD, PhD
Conflicts of Interest
Current research support from AAAAI Foundation, IFM Therapeutics, UCSD Department of Pediatrics; advisory boards for SOBI, Inc. and Novartis; research collaboration with Regeneron, Inc.
Faculty
Jennifer Leiding, MD
Conflicts of Interest
No relevant financial relationships with ineligible companies
Faculty
Paul J. Maglione, MD, PhD
Conflicts of Interest
No relevant financial relationships with ineligible companies
Faculty
Richard Wasserman, MD, PhD
Conflicts of Interest
No relevant financial relationships with ineligible companies
The IgNS planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Nursing Continuing Professional Development
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider #5-115. This program is approved for up to 2 hours of continuing nursing education. Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida, and the District of Columbia.
Pharmacy Continuing Education
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for up to 2 hours of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
(Universal Activity Number – 0761-9999-23-514-H01-P)
Type of Activity: Knowledge, Skills/Strategy
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their
own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive CE credit, learners must follow these steps:
- Review the objectives and disclosures
- Study the educational content
- Complete the activity evaluation at the end of the activity
For Pharmacists: Upon completing the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.